Skip to content
Logo APM
  • Login
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
    • Māori
Advanced
  • Minimal residual disease negat...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Save to List
  • Permanent link
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Saved in:
Bibliographic Details
Main Authors: Aurore Perrot, Valérie Lauwers‐Cancès, Jill Corre, Nelly Robillard, Cyrille Hulin, Marie‐Lorraine Chrétien, Thomas Dejoie, Sabrina Mahéo, Anne-Marie Stoppa, Brigitte Pegourié, Lionel Karlin, Laurent Garderet, Bertrand Arnulf, Chantal Doyen, Nathalie Meuleman, Bruno Royer, Jean‐Richard Eveillard, Lotfi Benboubker, Mamoun Dib, Olivier Decaux, Arnaud Jaccard, Karim Belhadj, Sabine Bréchignac, Brigitte Kolb, Cécile Fohrer, Mohamad Mohty, Margaret Macro, Paul G. Richardson, Victoria Carlton, Martin Moorhead, Thomas A. Willis, Malek Faham, Kenneth C. Anderson, Jean‐Luc Harousseau, Xavier Leleu, Thierry Façon, Philippe Moreau, Michel Attal, Hervé Avet‐Loiseau, Nikhil C. Munshi
Format: Artigo
Language:English
Published: 2018
Online Access:https://doi.org/10.1182/blood-2018-06-858613
Tags: Add Tag
No Tags, Be the first to tag this record!
  • Holdings
  • Description
  • Comments
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1182/blood-2018-06-858613

Similar Items

  • Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
    by: Perrot, Aurore, et al.
    Published: (2018)
  • Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study
    by: Murielle Roussel, et al.
    Published: (2016)
  • Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02
    by: Xavier Leleu, et al.
    Published: (2013)
  • Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma
    by: Dejoie, Thomas, et al.
    Published: (2016)
  • Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma
    by: Thomas Dejoie, et al.
    Published: (2016)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs

Our networks:

  • Facebook Instagram Linkedin Youtube Spotify Tiktok

Developed by

Logo de acervos digitais